Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children

Guyader, N. Le; Auvrignon, Anne; Vu-Thien, Hoang; Portier, E; Tabone, Marie‐Dominique; Leverger, Guy

doi:10.1007/s00520-004-0641-2

Cited by 18 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corapcioglu et al 9 and Uygun et al 22 demonstrated that PIP/TAZO monotherapy showed no inferiority to cefepime treatment in pediatric FN with cancer. The treatment success without modification in the PIP/TAZO group in our study of 59.6% was in agreement with other reports in which the study population consisted of both hematological malignancies and solid tumors 9, 22–24. The treatment success without modification for PIP/TAZO with or without aminoglycoside was 56% by Corapcioglu et al 9, 60% by Uygun et al 22, 77% by Le Guyader et al 23, and 42% by Aksoylar et al 24.…”

Section: Discussionsupporting

confidence: 91%

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Ichikawa

Suzuki

Ohshima

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Ichikawa

Suzuki

Ohshima

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…PIPC/ TAZ monotherapy was reported not to be inferior to CFPM monotherapy in pediatric patients with FN [8,9]. In our study, the overall treatment success rate without modifications in the TAZ/ PIPC group was 62.1%, which was consistent with the findings of previous studies [8][9][10][11][12]. We examined several other parameters, including success rates in patients with absolute neutrophil counts less than 0.5 Â 10 9 /l at the end of the treatment, the rate of new infections, success rates in patients with bacteremia, and mortality, in order to compare the effectiveness of the two drugs; however, no differences were observed in these parameters.…”

Section: Discussionsupporting

confidence: 92%

Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study

Sano

Kobayashi

Suzuki

et al. 2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

To evaluate the efficacy and safety of piperacillin/tazobactam (PIPC/TAZ) or cefepime (CFPM) monotherapy for febrile neutropenia (FN) in children, a total of 53 patients with 213 febrile episodes were randomly treated with either PIPC/TAZ 337.5 mg/kg/day, or CFPM 100 mg/kg/day. No significant differences were observed in the success rates of the PIPC/TAZ and CFPM treatments (62.1% vs. 59.1%, P = 0.650). Furthermore, no differences were noted in the rates of new infection and mortality, and no serious adverse effects occurred in either of groups. Both PIPC/TAZ and CFPM were effective and safe as an empirical therapy for FN in children. Pediatr Blood Cancer 2015;62:356-358. © 2014 Wiley Periodicals, Inc.

show abstract

“…Some combination regimens include cefepime plus amikacin [23,24], piperacillin-tazobactam plus netilmicin [25,26], and meropenem plus amikacin [25] combinations.…”

mentioning

confidence: 99%

Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid Tumors

Demir

Kutluk

Ceyhan

et al. 2011

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Febrile neutropenia (FEN) is a leading complication of intensive chemotherapy. With this prospective randomized study, the authors aimed to compare the effectiveness of sulbactam-cefoperazone (SC) versus carbapenems, as empirical monotherapy in febrile neutropenic children with lymphoma and solid tumors. Febrile neutropenic children (age ≤16 years) hospitalized at the authors' center for lymphomas or solid tumors between March 2007 and June 2009 were included in the study. Patients randomly received SC or carbapenem. Patients were reevaluated at 72 hours and in case of persistent fever, an aminoglycoside and/or a glycopeptide was added to the antibiotic treatment. When a resistant pathogen was isolated, the antibiotic therapy was modified. Treatment responses was defined as success without modification, overall success, or failure. Two hundred and eight episodes were documented in 128 patients (F/M: 56/72), with a median age of 7 years (0.5-17.4 years). Absolute neutrophil count and duration of neutropenia in patients treated with SC and carbapenems were 133/mm(3) (0-500) and 113/mm(3) (0-500), and 4 days (1-21) and 5 days (2-20), respectively. In the SC and carbapenem groups, 82 (78.8%) and 84 episodes (80.7%) improved with treatment, whereas 21 (20.2%) and 19 (18.3%) episodes required treatment modification respectively. One patient from each treatment group died according to febrile neutropenia. The overall success rates were 99% in both groups (P = .94). Empiric SC therapy was found to be as effective as carbapenem monotherapy in pediatric febrile neutropenic patients with lymphoma and solid tumors.

show abstract

Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children

Abstract: This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenic children. It allowed us to maintain the bacterial ecology of our unit.

Cited by 18 publications

References 20 publications

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia

Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study

Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid Tumors

Contact Info

Product

Resources

About